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Background: Auditory verbal hallucinations (AVH) are experienced more frequently by
patients with borderline personality disorder (BPD) than previously assumed. However,
consensus is lacking on how to treat them.
Objective: To provide a systematic review of studies reporting on AVH in patients with
BPD, with a focus on the efficacy of treatment of psychotic symptoms.
Methods: For this review a systematic search was made in the PubMed and Ovid
databases, and mean weighted prevalence rates, adjusted for sample size, were
computed.
Results: The search yielded 36 studies describing a total of 1,263 patients. Auditory
hallucinations (including AVH) were reported in 27% of hospitalized BPD patients; AVH
were reported in 25% of all patients and in 24% of outpatients. Of the hallucinating
patients, 78% experienced AVH at least once per day, for a duration of several days
to many years. On the whole, patients with BPD regarded their voices as malevolent and
omnipotent in nature. Compared to patients with schizophrenia, the phenomenological
characteristics of AVH were similar and the ensuing distress was equal or even higher,
whereas scores for other positive symptoms were lower. The presence of AVH in BPD
was associated with an increase of suicide plans and attempts, and more frequent
hospitalization. Moreover, AVH in the context of BPD were associated with higher
prevalence rates for post-traumatic stress disorder and emotional abuse. The efficacy of
antipsychotics was investigated in 21 studies. Based on these studies, we conclude that
both typical and atypical antipsychotics tend to have positive effects on AVH experienced
in the context of BPD. The efficacy of cognitive-behavioral therapy and non-invasive brain
stimulation has not yet been systematically assessed.
Conclusions: These findings indicate that AVH experienced in the context of BPD are
in need of proper diagnosis and treatment, and that antipsychotics tend to be beneficial
in treating these (and other psychotic) symptoms.There is an urgent need for studies
assessing the efficacy of cognitive-behavioral therapy and non-invasive brain stimulation
in this underdiagnosed and undertreated group.
Keywords: prevalence, phenomenology, psychotic symptoms, childhood trauma, comorbidity
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INTRODUCTION
Auditory verbal hallucinations (AVH) are voices perceived
during wakefulness, in the absence of an external origin (9).
The highest prevalence of these phenomena is in patients
diagnosed with schizophrenia [i.e., 70–80%, (10)]. In these
patients they tend to also yield high levels of distress which
may lead to destructive behavior, such as suicide and homicide
(11, 12). Although less well-known, AVH are experienced
in the context of borderline personality disorder (BPD) as
well (10, 13, 14). BPD is a severe psychiatric disorder
with a lifetime prevalence rate of 1–3% in the general
population (15, 16). It is conceptualized as an emotion-
regulation disorder (17), characterized by unstable relationships,
identity disturbances, and self-destructive behavior. Comorbidity
with depression and other psychiatric disorders is high (18).
AVH experienced by patients with BPD have long been
characterized as “pseudohallucinations,” since they were thought
to be mild and phenomenologically different from those in
schizophrenia (19). This line of thought is still reflected
in the operational criteria for BPD featuring in the fifth
edition of the Diagnostic and Statistical Manual of Mental
Disorders [DSM-5; (20)], which states that, “Some individuals
develop psychotic-like symptoms (e.g., hallucinations, body-
image distortions, ideas of reference, hypnagogic phenomena)
during times of stress.” However, valid definitions for terms
like “pseudohallucination” and “psychotic-like” symptoms are
lacking (9).
Furthermore, there are indications that AVH are frequent and
severe in the context of BPD, and that their phenomenological
characteristics do not differ essentially from those of AVH
in patients diagnosed with schizophrenia (2). Therefore, we
prefer to regard AVH in patients with BPD as genuine
hallucinations.
Rationale
Because of the burden caused by AVH in the context
of BPD, and the ensuing risk of hospitalization and
an unfavorable outcome, there is an urgent need for
effective treatment of these perceptual phenomena
(21, 22).
Objective
Since therapeutic guidelines for this specific purpose are lacking,
this study aims to present a systematic review of the literature on
AVH in BPD, with special focus on the efficacy of treatment for
psychotic symptoms in this patient group. Therefore, the aim of
this study was to answer the following questions in patients with
BPD:
1. What is the prevalence of AVH?
2. What are the phenomenological characteristics and severity of
AVH?
3. What is the association between AVH and comorbid disorders
and childhood trauma?
4. What is the efficacy of treatment of psychotic symptoms?
METHODS
Study Design
A systematic review was conducted of studies reporting on the
treatment of AVH and other psychotic symptoms in the context
of BPD.
Search Strategy
A systematic search was performed using the PubMed and Ovid
databases from 1806 through April 2017 (Medline 1946-, Embase
1974-, PsycINFO 1806-, Cochrane DSR, ACP, Journal Club,
DARE, CCTR, CMR, HTA, NHSEED).
The following search terms were used: hallucination,
auditory hallucination, auditory verbal hallucination,
delusions, hallucinations, acute psychosis, childhood psychosis,
hallucinosis, “paranoia (psychosis),” schizophrenia, affective
psychosis/ or alcoholic psychosis/ or reactive psychosis/ or toxic
psychoses, borderline state, “fragmentation (schizophrenia),”
psychoticism, schizophreniform disorder, schizotypy,”
positive and negative symptoms,” paranoid schizophrenia,
undifferentiated schizophrenia, antipsychotic (drugs/agents),
neuroleptic (drugs/agents), cognitive-behavioral therapy,
behavior therapy, cognitive therapy, brain stimulation, direct-
current stimulation, transcranial magnetic stimulation, clinical
study, and borderline personality disorder.
Data Sources, Studies Selections, and
Data Extraction
Articles were considered eligible for inclusion when they
were written in English and presented original data either
regarding auditory (verbal) hallucinations in patients with
a primary diagnosis of BPD, or regarding the efficacy of
antipsychotics, cognitive-behavioral therapy (CBT), non-invasive
brain stimulation or the effects on treatment on the severity
of (specific) psychotic symptoms in patients with BPD. The
rationale to explore these interventions is that the first treatment
option for hallucinations in schizophrenia spectrum disorders
is antipsychotic medication, which can induce a rapid decrease
in severity (23). CBT can be applied as an augmentation to
antipsychotic medication, thereby reducing anxiety and distress.
Transcranial magnetic stimulation (TMS) is an experimental
treatment method aimed at reducing the frequency and severity
of auditory hallucinations.
Cross references were systematically assessed and checked via
Google Scholar.
Data Analysis
Mean weighted prevalence rates were computed using SPSS
version 23.0. The total number of patients with AVH was divided
by the total number of patients who participated into the studies
presenting prevalence rates.
The severity of other psychotic symptoms was explored in
a population of 107 outpatients with BPD with and without
hallucinations (14). In that study, the presence of hallucinations
was associated with the presence of delusions, but not with
negative symptoms and disorganization. For the present review,
additional analyses were performed to investigate comorbid
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psychotic symptoms in patients with BPDwith and without AVH
(n = 101). For this, patients were divided into two groups: (i)
patients with AVHoccurring at least weekly, and (ii) patients with
less frequent AVH or no AVH at all.
To investigate an association between AVH and comorbid
disorders and childhood trauma, we repeated the analyses (in
which associations between hallucinations and the number of
comorbid psychiatric disorders, and PTSD and emotional abuse
were established) of the study by Niemantsverdriet et al. (14)
for BPD patients with and without AVH. For this, a logistic
regression with backward selection was used to examine the
association between AVH and specific comorbid psychiatric
disorders. These disorders were clustered into three groups,
i.e., mood disorders (unipolar depression, bipolar I and II
disorder), post-traumatic stress disorder (PTSD), and substance
use disorders (i.e., alcohol abuse and dependence, drug abuse and
dependence, or both).
Furthermore, we used a proportional odds model with
backward selection to study the association between AVH and
five subtypes of childhood trauma.
RESULTS
The literature search yielded 569 publications on AVH and/or the
use of antipsychotics in patients with BPD. Of these, 36 studies
(with a total of 1,263 patients) were potentially eligible for this
systematic review. Thirty-six studies were considered eligible for
inclusion: 15 on AVH (with a total of 677 patients) and 22 on
the treatment of psychotic features. One study was included in
both systematic reviews. Of the latter 22 studies, 21 assessed the
efficacy of antipsychotic medications in a total of 572 patients.
Reasons for exclusion are described in Figure 1. An overview of
the included studies is presented in Table 1, 2. In one study, the
efficacy of combined early intervention for BPD and specialized
first-episode psychosis treatment was explored (54).
Prevalence Rates of AVH
Of the 15 studies on AVH, six studies reported the prevalence
rates for auditory hallucinations and AVH in 21–46% of the
patients, the mean weighted point prevalence of AVH was
25% (14, 19, 29). With the exception of some patients in the
study of Kingdon et al. (29), all study populations consisted of
outpatients. For outpatients, the mean weighted point prevalence
of AVH was 24%. In two patient samples of up to 37 hospitalized
patients, the prevalence of auditory hallucinations ranged from
21 to 38% (25, 26) with a mean weighted prevalence of
27%. The lifetime prevalence for auditory hallucinations was
50% (32).
Phenomenology and Severity of AVH
In the studies in this review, the mean frequency of AVH
in BPD ranged from once per day to once per hour, with
each episode lasting several minutes or more (2, 14, 29).
The mean onset of AVH was reported to be up to 18
years previously (2, 14, 19, 32). About half of the patients
reported more than one voice (19, 32), speaking in the second
person and, sometimes, in the third person (32). These voices
were experienced as “comments” by 61% of the patients and
as “dialogues” by 40% (33); in addition, 56% experienced
imperative hallucinations (21). Control over the voices was
FIGURE 1 | Flowchart of literature search on borderline personality disorder, auditory verbal hallucinations and antipsychotics.
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TABLE 1 | Studies included in the present review (n = 15).


















Inpatients DIB SSI, Meehl scale – AH 21%
Suzuki et al. (27) 5 females Inpatients DSM IV – – NA Case report
Yee et al. (19) 171 (90%
female)






Barnow et al. (28) 1 female Inpatient – – – NA Case report
Kingdon et al. (29) 33 (76%
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Slotema et al. (22) 89 (92%
female)
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heard/saw/tasted/ smelled
or felt something that other
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Slotema et al. (21) 38 females Outpatients SCID II PSYRATS BAVQ, SCRS,
VPDS
NA Overlap with (14)
AH, auditory hallucinations; AVH, auditory verbal hallucinations; BAVQ, Beliefs About Voices Questionnaire; CTQ, Childhood Trauma Questionnaire; DES, Dissociative Experience Scale;
DIB-R, Diagnostic Interview for Borderlines Revised; DIBP, Diagnostic Interview for Borderline Patients; MINI Plus, Mini International Neuropsychiatric Interview Plus; NA, not applicable;
PANSS, Positive And Negative Syndrome Scale; PSE, Present State Examination; PSYRATS, Psychotic Symptom Rating Scales; SCID II, Structured Clinical Interview for DSM IV axis
2 Personality Disorders; SCID-D, Structured Clinical Interview for DSM IV dissociative disorders; SCL-90, Symptom Check List 90 items; SCRS, Social Comparison Rating Scale; SSI,
Schizotypal Symptom Inventory; VPDS, Voice Power Differential Scale.
virtually absent (2, 14, 19, 29). In four case reports (describing
seven outpatients and nine inpatients), 75% were criticized
by their voices, whereas commands (e.g., to hurt themselves)
were perceived by 50% (24, 27, 28, 30). The duration of
experiencing episodes with AVH ranged from several days to
many years (24, 27, 28, 30). Voices are present, in particular,
during times of stress (24, 27, 30). Compared to individuals
with AVH without a psychiatric disorder, patients with BPD
and AVH tend to show much higher scores on the majority
of items on AVH questionnaires [e.g., “frequency,” “duration,”
and “controllability”; (2)]. Regarding the phenomenological
characteristics of AVH in BPD, no differences were found
compared to those reported in schizophrenia (2, 29, 32,
33)].
The content of voices in BPD tends to be negative and critical
(2, 14, 19, 29). Compared to patients with schizophrenia, the
ensuing distress was equal to or even higher in patients with
BPD (2, 29). This is in marked contrast with AVH experienced by
individuals without a psychiatric diagnosis, which tend to be less
frequent, mild and often benevolent (2). Two studies explored
beliefs about voices (21, 31). In 10 patients with BPD, in 23
with schizophrenia and in 12 patients with both disorders, no
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BPRS, Brief Psychiatric Rating Scale; CGI-BPD, Clinical Global Impression for Borderline Personality Disorder; HSCL-90, Hopkins Symptom Checklist 90; IMPS, Inpatients
Multidimensional Psychiatric Scale; PANSS pos, Positive And Negative Syndrome Scale positive items; RCT, randomised controlled trial; SCL-90, Symptom Checklist 90; SIB, Schedule
for Interviewing Borderlines; SIB, Schedule for Interviewing Borderlines; SPD, schizotypal personality disorder.
substantial differences were found regarding beliefs about the
power and malevolent intent of the participants’ dominant voices
(31); in all groups, the scores on these items were high. The
majority of a sample of 38 patients with BPD with AVH rated
their voices as malevolent and omnipotent, as well as higher in
social rank than themselves (21).
The risks for suicidal attempts and hospitalization, associated
with AVH, were explored in a sample of 27 outpatients with BPD
and AVH, and in 62 without AVH (22). The presence of AVH
was associated with a significantly higher incidence of suicidal
plans and attempts in the month prior to study participation, a
greater number of hospitalizations, and a shorter interval until
hospitalization. In the latter study, the Psychotic SymptomRating
Scales (PSYRATS) was used as an outcome measure (55). All
subscales of the PSYRATS showed a positive correlation with
suicide plans. The phenomenological subscale and the subscale
for distress due to AVH also showed a positive correlation with
suicide attempts. Moreover, higher scores for distress due to AVH
were associated with more frequent hospital admissions.
The severity of other psychotic symptoms was explored in
a population of 107 outpatients with BPD with and without
hallucinations (14). For the present review, additional analyses
were performed to investigate comorbid psychotic symptoms
in patients with and without AVH (n = 101). Of the 28
hallucinating patients, 78% experienced AVH at least once per
day, 79% experienced at least one hallucination in a different
sensory modality (i.e., visual, tactile, olfactory or gustatory),
and 61% experienced additional hallucinations in multiple
sensory modalities. Among patients with AVH, delusions were
present in 44% of the cases, hallucinatory behavior in 70%, and
suspiciousness and/or ideas of persecution in 33%.
In another study, the severity of positive symptoms in
patients with BPD who experienced AVH was compared to
that in patients with schizophrenia and AVH (33). In the year
prior to study inclusion, in 23 patients with schizophrenia
and in 21 patients with BPD, the scores for most items on
the Positive and Negative Syndrome Scale (56), i.e., delusions,
conceptual disorganization, grandiosity, and negative symptoms,
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were higher for the schizophrenia group. Scores for BPDwere the
same as found in the present study.
In a case series of 10 patients with BPD, Yee et al. (19)
explored the co-occurrence of hallucinations in various sensory
modalities. In their group, 30% experienced visual and olfactory
hallucinations in addition to their AVH, while all of them (100%)
reported thought insertion, 90% thought blocking or withdrawal,
and 70% the sensation of being under the influence of some
external power. In four other case reports (describing a total of 16
patients), AVH were regularly accompanied by visual, olfactory,
and tactile hallucinations, as well as by paranoid delusions. In
addition, one patient experienced ideas of reference (24, 27, 28,
30).
Comorbid Disorders and Childhood
Trauma
Very few studies have investigated the association between AVH
and comorbid psychiatric disorders. Tschoeke et al. (33) explored
childhood abuse and dissociative disorders in 23 BPD patients
with AVH, and in 21 patients with schizophrenia. The BPD
patients more frequently reported childhood trauma, notably
emotional abuse and neglect. Moreover, the BPD patients scored
higher than the schizophrenia patients on scales for emotional
and physical abuse and neglect, and on scales for sexual abuse.
Major dissociative disorders were present in 96% of the BPD
patients (78% dissociative disorder not otherwise specified, and
18% dissociative identity disorder), whereas they were absent in
patients diagnosed with schizophrenia. We repeated the analyses
of the study by Niemantsverdriet et al. (14) for BPD patients with
and without AVH. A best fit was achieved by including PTSD
and excluding mood disorders and substance use disorders. For
patients with PTSD, the odds ratio (OR) for experiencing AVH,
as compared to patients without PTSD, was 2.7 (CI 1.2–7.2,
p = 0.021). No significant associations were found between
the presence of AVH and comorbid mood or substance-use
disorders. In addition, our analyses showed that the median
number of comorbid diagnoses was higher for BPD patient with
AVH than for those without (four vs. three, respectively; Kendall’s
tau-b 0.199, p = 0.021). In addition, a best fit was achieved for
emotional abuse by dropping the variables for the other four
subtypes, i.e., sexual abuse, physical abuse, and physical, and
emotional neglect. The OR for emotional abuse was 1.1 (CI
1.014–1.220, p= 0.024).
Treatment of Psychotic Symptoms in
Patients With BPD
Our search yielded 21 studies on treatment with antipsychotics in
BPD, describing a total of 572 patients (Table 2).
We found no comparable studies in the field of CBT or
non-invasive brain stimulation, i.e., transcranial direct current
stimulation (tDCS) and TMS. However, Gleeson et al. (54)
reported on a randomized controlled pilot study with 16
patients (aged 15–25 years) in which they compared combined
specialist first-episode treatment plus specialist early intervention
for borderline personality, entitled Helping Young People
Early (HYPE; using an integrated, team-based intervention
model comprising time-limited cognitive-analytic therapy, case
management, and general psychiatric care) with specialist first-
episode treatment (SFET) alone (2012). Their aim was to
provide treatment for both psychosis and borderline personality.
Although the numbers were too small to allow for significance
testing or the calculation of effect sizes, the HYPE+ SFET group
showed fewer positive psychotic and negative symptoms, less
severe anhedonia and depression, better functioning, and better
adherence to medication than the SFET group. However, a larger
randomized controlled trial (RCT) is needed to confirm these
results.
In four studies describing antipsychotic treatment for patients
with BPD and psychotic features/disorders (34, 35, 44, 45), one
included only treatment-resistant psychotic patients with BPD,
which were subsequently recruited for a larger study on the
efficacy of clozapine for treatment-resistant psychotic patients
(44). In three of the four studies, the severity of psychotic
phenomena decreased. The other studies included patients with
BPDwithout distinctions for psychotic features. Of the 21 studies
investigating the efficacy of antipsychotic medication, nine were
RCTs with 215 patients in the active condition and 205 in
the placebo condition (34–42). In three of these studies the
severity of psychotic symptoms was explored, but no decrease
in severity was found in any of them. Paranoid symptoms
diminished in six out of nine studies; the remaining 12 were
open-label, naturalistic, or case studies, with a total of 152
patients. After treatment with antipsychotic medication, the
severity of psychotic symptoms was reduced in all six studies
that assessed this, and the severity of paranoid symptoms was
reduced in six of eight studies. The severity of hallucinations
was included as an outcome measure in only one study (44);
in that study clozapine reduced the severity of therapy-resistant
AVH. No clinical trials were found in which the severity of
AVH was used as an outcome measure. However, AVH subsided
after treatment with antipsychotics in two patients described
in a case report (27). The antipsychotic dosages used in seven
studies were 1,3 up to 5 times lower compared to those regularly
used for patients with psychotic disorders (34, 35, 37, 38, 42, 43,
45), while the other studies applied regular dosages. However,
antipsychotics were effective in reducing psychotic symptoms,
even at low dosages. In one study, the effect of quetiapine was
explored in patients with BPD, drug-induced psychosis, and
schizophrenia (51). At the end of that study, the mean scores
of each rating scale were significantly lower in the population as
a whole, and also within each diagnostic group. The percentage
improvement was significantly greater in patients with drug-
induced psychosis than in those with schizophrenia or BPD.
The mean weighted percentage of dropouts in patients using
typical antipsychotics was 36 and 43% for atypical antipsychotics.
Among the atypical antipsychotics, side effects occurred with the
following mean weighted percentages: 42% for sedation, 78% for
drooling, 44% for weight gain, 29% for nausea, 22% for dizziness,
11% for tremor, 11% for anxiety, 18% for irritability, 63% for
increased appetite, 38% for dry mouth, 15% for akathisia, 13%
for confusion, 14% for insomnia, 11% for headache, and 5% for
other side effects. The mean weight gain associated with the use
of olanzapine ranged from 1.3 to 4.5 kg. The side effects of the
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typical antipsychotic thioridazine (the only publication of typical
antipsychotics reporting side effects) were dry mouth (58%),
dizziness (50%), sedation (42%), weight gain (33%), constipation
17%, and akathisia (8%).
DISCUSSION
This systematic review presents an update on auditory verbal
hallucinations (AVH) among patients with borderline personality
disorder (BPD), with a special focus on the efficacy of
treatments for psychotic symptoms. It was found that AVH in
BPD are generally severe and in need of effective treatment.
Auditory hallucinations, including AVH, were reported in 27% of
inpatients with BPD. AVHwere experienced in 25% of all patients
and in 24% of the outpatients. These results are positioned
between the prevalence rates for AVH in the general population,
i.e., 9% (4, 7), and in schizophrenia [70–80%, (10)]. Of all patients
with BPD and AVH, 78% perceived their AVH at least once per
day and the ensuing distress was rated as high. The duration
of experiencing AVH ranged from several days to many years.
These findings are in contrast with the older literature which
characterizes AVH in the context of BPD as mild and transient
(20, 57). Furthermore, the phenomenological characteristics
of AVH in patients with BPD do not differ from those in
schizophrenia, and the ensuing distress might be even higher.
Patients with BPD tend to experience their voices as malevolent
and omnipotent, and higher in social rank than themselves. These
findings are in line with those for schizophrenia (31, 58). The
majority of BPD patients with AVH experienced hallucinations
in at least one other sensory modality, with visual hallucinations
being the most prominent. Scores for delusions were positive
in 44% of the patients, and for suspiciousness and ideas of
persecution in 33%. However, compared to patients diagnosed
with schizophrenia, the overall scores for positive and negative
symptoms were lower in patients with BPD (10, 33).
The prevalence rate for imperative hallucinations of 56%
is in line with the findings that the presence of AVH in
the context of BPD was associated with an increase in the
incidence of suicidal plans and attempts, as well as with the
number of hospitalizations. The same applies for suicidality in
patients with AVH in schizophrenia spectrum disorders (59,
60). Comorbidity (e.g., with mood disorders and substance
use disorders) has sometimes been held responsible for the
occurrence of AVH in patients with BPD (3). In two studies the
relationship of AVH with comorbidity and childhood trauma
was investigated. In the present BPD group, PTSD was the only
comorbid disorder associated with AVH. Comorbid dissociative
disorders were more prevalent among patients with AVH and
BPD compared to those with schizophrenia (33). The number
of patients with childhood abuse was higher in BPD patients
with AVH than in those without AVH. These findings are similar
to those for childhood abuse reported for psychotic disorders
(61).
Psychotherapies, notably dialectical behavior therapy, are
effective for BPD core pathology and associated general
psychopathology (62, 63). Of the 22 studies that assessed the
efficacy of treatments for psychotic features in patients with
BPD, only one assessed the efficacy of a first-episode specialty
program, and none evaluated the efficacy of CBT, tDCS or rTMS
for AVH. In most studies the severity of psychotic symptoms
and paranoid delusions decreased with the use of antipsychotics;
however, there were considerable dropouts and side effects (the
most common being drooling, increased appetite, sedation, dry
mouth, and weight gain).
Although the number of studies was low, these findings
indicate that antipsychotics tend to have a beneficial effect
on psychotic symptoms experienced in the context of BPD.
Moreover, it should be noted that, since the majority of
studies (i.e., 17 of 21) included patients with and without
psychotic symptoms, the antipsychotics would probably have
shown greater benefit if patients with psychotic symptoms
alone would have been included. Furthermore, the effects of
antipsychotics are expected to increase with higher dosages.
These results are in line with other meta-analyses which
found small to moderate effect sizes for antipsychotics in
the treatment of psychotic symptoms in patients with BPD
(64–66). In one study, the effects of antipsychotics did not
differ from those in patients with schizophrenia (51). Finally,
patients with BPD and psychotic disorders might benefit from a
combination of a specialist first-episode treatment plus specialist
early intervention for borderline personality, as investigated by
Gleeson et al. (54).
Implications for Clinical Practice and
Future Research
The findings presented in this systematic review have four
main implications. Firstly, AVH among patients with BPD
are common. Since they are associated with high levels of
distress and their consequences can be severe, these patients
deserve appropriate treatment for their AVH. This is in
contrast with the older literature, where psychotic symptoms
are sometimes dismissed as “psychotic-like” symptoms or
“pseudohallucinations” and, therefore, do not get the attention
they deserve (30). Secondly, our findings indicate that the
psychotic symptoms experienced by patients with BPD resemble
those experienced by patients diagnosed with schizophrenia
(although delusions, negative symptoms and disorganization are
less common). Therefore, AVH as experienced in the context
of BPD appear to lie on a continuum with those in individuals
without a psychiatric diagnosis, and those with schizophrenia.
This is in line with the original meaning of the term “borderline
disorder” which was introduced to designate a condition in
the borderline area between neurotic and psychotic disorders,
with the possibility of occasional transgressions of the border in
either direction (67). Although even BPD patients with persistent
hallucinations are rarely diagnosed with a DSM-5 diagnosis of
schizophrenia spectrum disorder (30), we argue that, in specific
cases, it would be better to diagnose both disorders and offer
treatment accordingly, especially when the distress caused by
those hallucinations is high. Thirdly, our findings also imply
that patients with BPD and psychotic symptoms are likely to
benefit from antipsychotic medication. When side effects are
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mild or absent, there is no reason to withhold these patients
from higher dosages if lower dosages fail to yield adequate effects.
Fourth and finally, patients with BPD and AVH might benefit
from other treatments for psychotic disorders, such as CBT
and non-invasive brain-stimulation techniques (1, 5). In CBT,
control over symptoms and problems can be obtained with the
aid of a personalized case formulation. Of special interest is the
frequent presence of command hallucinations in BPD, which
may lead to suicidal behavior (68). These patients might benefit
from CBT specifically designed for the treatment of command
hallucinations (69). rTMS and tDCS are thought to normalize
increased brain activity with a rapidly changing magnetic field,
and a low-intensity current, respectively. Patients undergo these
treatment under full consciousness. If applied in conformance
with international safety guidelines. The modalities rTMS and
tDCS are safe and their side effects (if present) are temporary and
mild. Moreover, non-invasive brain stimulation is beneficial in
patients with psychotic features and AVH (6, 8, 70–72).
Limitations
An important limitation of the present study is the relatively low
number of original studies and numbers of patients included
per study. Moreover, the use of differing assessment methods
and questionnaires in the original studies makes it difficult
to directly compare their findings, and is therefore a minor
limitation.
CONCLUSIONS
AVH have a mean weighted prevalence of 26% in patients
with BPD. They tend to be experienced as severe and their
phenomenological characteristics do not differ from those in
patients diagnosed with schizophrenia. These findings emphasis
the need for proper diagnosis and appropriate treatment.
There is some evidence that antipsychotics are effective
in the treatment of psychotic symptoms in patients with
BPD. In addition, these patients might benefit from other
treatments for psychosis, such as CBT and non-invasive brain
stimulation. Future studies should be directed at assessing the
effects of such treatment strategies for this underserved
subpopulation.
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